


# Phase IIIb COMBI-APlus

## COMBI-APlus

Image



### 2020105

Atkinson, V. et al. Eur. J. Cancer 2022; 163: 79-87

Atkinson, V. et al. Asia Pac. J. Clin. Oncol. 2016; 12(suppl 7): 5-12

<sup>10</sup>

Guidelines from Australian melanoma medical oncologists<sup>20</sup>

COMBI-AD Grade3/4



n(%)	COMBI-APlus (n=552)	COMBI-AD** (n=435)
発熱イベント発生率 [95%CI]	44 (8.0) [5.9-10.6]	87 (20.0) [16.3-24.1]
Grade3/4の発熱	21 (3.8)	23 (5.3)
発熱による入院	24 (4.3)	46 (10.6)
発熱による治療中止	13 (2.4)	38 (8.7)

\*Clopper-Pearson

\*\*

Atkinson, V. et al. Eur. J. Cancer 2022; 163: 79-87  
 3  
 10

- 552 541 98 374 68 175 32 CPK 154 28
- Grade3 226 39 CPK 32 21
- 81 85 89
- 2 1 1

2020 10 5

Atkinson, V. et al. Eur. J. Cancer 2022; 163: 79-87  
 3  
 10

Source URL: [https://www.pro.novartis.com/jp-ja/products/tafmek/mel/clinical\\_02](https://www.pro.novartis.com/jp-ja/products/tafmek/mel/clinical_02)